Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-23	US$1.160	-8.66%	3,727,473
26-07-22	US$1.270	-7.97%	1,990,449
26-07-21	US$1.380	-4.17%	2,181,809
26-07-20	US$1.440	-8.86%	1,718,822
26-07-17	US$1.580	+0.64%	1,249,349

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.160USD

Average target price

4.000USD

Spread / Average Target

+244.83%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-23 EDT			5-day change	1st Jan Change
1.160 ^USD	-8.66%		-26.11%	-50.21%

07-15	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ
07-14	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody	CI

Market Cap	67.17M 59.07M 54.88M 50.47M 94.65M 6.5B 96.35M 656M 256M 3.17B 252M 247M 11.01B	P/E 2024	-0.81x	P/E 2025	15.5x
Enterprise Value	67.17M 59.07M 54.88M 50.47M 94.65M 6.5B 96.35M 656M 256M 3.17B 252M 247M 11.01B	EV / Sales 2024	1,170,430x	EV / Sales 2025	-
Free-Float	77.54%	Yield 2024 *	-	Yield 2025	-

07-15	Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion	DJ
07-14	Innovent Biologics, Inc. and Spero Therapeutics, Inc. Announce Exclusive License Agreement for IBI355, Phase 2-Ready Third-Generation Anti-CD40L Antibody	CI
07-14	Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing	MT
07-14	Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion	RE
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Benchmark	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Index	CI
06-29	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Index	CI
06-28	Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index	CI
06-17	GSK says US FDA approves urinary tract infection treatment Utebzi	AN
06-17	GSK plc Receives US FDA Approval for Oral Antibiotic Tebipenem for Complicated Urinary Tract Infections	CI
06-17	GSK Secures US FDA Nod for Complicated Urinary Tract Infection Antibiotic	MT
06-17	GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections	MT
06-17	GSK, Spero Therapeutics Gain U.S. Approval for Utebzi	DJ

25-10-21	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
24-12-20	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
24-11-18	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
24-08-06	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
23-08-14	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT

Spero Therapeutics, Inc. Stock

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Valuation: Spero Therapeutics, Inc.

Chart: Spero Therapeutics, Inc.

Latest news : Spero Therapeutics, Inc.

Last Transcript: Spero Therapeutics, Inc.

Analysts' recommendations: Spero Therapeutics, Inc.

Press Releases: Spero Therapeutics, Inc.

News in other languages: Spero Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Spero Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-14	Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties	AQ
07-14	Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody	AQ
05-13	Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update	AQ
05-05	Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026	AQ
03-26	Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update	AQ

06-18	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
06-18	Star Warsh
06-18	MORNING BRIEFING - Deutschland/Europa -2-
06-17	GSK und Spero Therapeutics erhalten US-Zulassung für Utebzi
25-10-21	GSK et Spero publient des résultats positifs sur un antibiotique expérimental

1 day	-8.66%
1 week	-26.11%
Current month	-47.51%
1 month	-46.05%
3 months	-58.57%
6 months	-52.46%
Current year	-50.21%

1 week	1.1	1.57
1 month	1.1	2.34
Current year	1.1	3.08
1 year	1.1	3.08
3 years	0.51	3.22
5 years	0.51	19.87
10 years	0.51	23.64

Manager	Title	Age	Since
Esther Rajavelu CEO	Chief Executive Officer	47	2025-01-09
Timothy Keutzer COO	Chief Operating Officer	58	2023-01-31
Shai Biran IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Milind Deshpande CHM	Chairman	69	2013-12-31
Patrick Volkert Vink BRD	Director/Board Member	62	2015-08-31
Frank Thomas CHM	Chairman	56	2025-01-09

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/23/26	Milind Deshpande	Free	Director	30,000	0.0518%
6/23/26	Patrick Volkert Vink	Free	Director	30,000	0.0518%
6/23/26	John Pottage	Free	Director	30,000	0.0518%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPERO THERAPEUTICS, INC.	-8.66%	-26.11%	-51.26%	-20.00%	73.53M
WUXI APPTEC CO., LTD.	+1.23%	+0.35%	+51.62%	+87.98%	55.27B
ARGENX SE	+5.09%	+6.24%	+63.15%	+62.06%	54.15B
BIONTECH SE	+0.25%	+0.55%	-19.67%	-15.22%	23.22B
INSMED INCORPORATED	+0.72%	-0.05%	+3.84%	+409.54%	23.11B
WUXI BIOLOGICS (CAYMAN) INC.	-0.76%	+5.25%	+30.39%	-4.02%	20.33B
GENMAB A/S	-0.37%	+0.71%	+31.36%	-31.61%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.86%	+6.50%	+33.57%	+549.12%	15.76B
PHARMAESSENTIA CORPORATION	-2.54%	-8.73%	+164.11%	+289.45%	15B
EXELIXIS, INC.	+1.22%	-0.05%	+22.58%	+182.63%	13.82B
Average	-0.45%	-1.97%	+32.97%	+150.99%	23.86B
Weighted average by Cap.	+1.30%	+2.76%	+43.51%	+134.95%

	2024	2025
Net sales	47.98M 42.2M 39.2M 36.05M 67.61M 4.65B 68.82M 469M 183M 2.27B 180M 176M 7.86B	66.8M 58.75M 54.58M 50.2M 94.14M 6.47B 95.83M 653M 255M 3.16B 251M 245M 10.95B
Net income	-68.57M -60.3M -56.02M -51.52M -96.63M -6.64B -98.36M -670M -261M -3.24B -257M -252M -11.24B	8.57M 7.54M 7M 6.44M 12.08M 830M 12.3M 83.75M 32.67M 405M 32.18M 31.48M 1.4B
Net Debt	-	-